Kornimate/medical-research-clean huggingface dataset:
effectiveness of a butyrate formulation and butyrate + polyphenol formulation on gut health, permeability and associated symptoms

Conditions: Gut Health

Summary: the purpose of this study is the assess the effectiveness and safety of a butyrate formulation and a butyrate + polyphenol formulation on gut health, permeability and associated symptoms

this is a double-blind, randomized, placebo-controlled, remote design study to evaluate the effects of a butyrate formulation and butyrate + polyphenol formulation on gut health, intestinal permeability and associated symptoms. participants will be asked to complete laboratory assessments and questionnaires. a total of up to 105 subjects (35 subjects per arm) will be enrolled in a randomly assigned sequence for the 28-day period. there will be scheduled remote video calls during the study. the study subjects will complete assessment tools that include a rating scale for gastrointestinal symptoms, quality of life questionnaire for digestion, visual analogue scale of abdominal pain, stool form scale, global assessment of improvement scale-gastrointestinal and the short form-36 health survey (sf-36). laboratory testing will include an assessment of gut microbiome, analysis of short chain fatty acids, a panel for the gut barrier and intestinal permeability.

Eligibility criteria:
inclusion criteria: 1. ambulatory, male or female, 21-70 years of age 2. a bmi of 18.5 -34.9 3. . experiences at least three conditions involving gastrointestinal health on a weekly basis 4. are comfortable fasting overnight 5. are able to complete study procedures for up to approximately 6 hours on 2 separate days 6. considered to be generally healthy on the basis of medical history 7. willing to follow study instructions, including compliance with the study procedures and requirements exclusion criteria: 1. unable to provide a urine specimen, stool specimen or blood sample from a finger stick 2. currently on a galactose/lactose restricted diet 3. having taken proton pump inhibitors within the past 3 months 4. history of oral antibiotic use within the past 3 months 5. current or previous history of gastrointestinal disease, cancer, infection or surgery that may interfere with the outcome parameters 6. a medical or surgical event requiring hospitalization, outpatient visits or emergency room visits within the past 5 years or in the judgment of the study investigator /sub-i would preclude participation in the study 7. current or previous history of diabetes 8. history of a major change in dietary habits with the past 1 month 9. known intolerance or allergy to sugar alcohols including mannitol, sorbitol, xylitol, lactulose or lactose 10. women who are lactating, pregnant or planning pregnancy within the next two months 11. having donated blood or received a blood transfusion within 30 days before screening 12. currently participating in another clinical research study or participated in another clinical research study within 30 days prior to screening

Keywords: gastrointestinal discomfort abdominal pain gas bloating diarrhea constipation heartburn abdominal discomfort
analysis of disturbances in neurofluid dynamics in type i chiari malformations

Conditions: Type I Chiari Malformation; Cerebral Hemodynamic; Craniospinal Hydrodynamic; Phase Contrast MRI; Cerebrospinal Fluid

Summary: a global analysis of craniospinal hemodynamics and hydrodynamics is necessary to better understand the pathophysiology of chiari malformations. this includes an analysis of intraventricular csf flow, intracranial subarachnoid spaces, foramen magnum, cervical subarachnoid spaces and within the syringomyelia cavity when present. the investigators will also analyze the pulsatility of the cerebellar tonsils in the foramen magnum. hemodynamic analysis will be performed at the high cervical level (internal carotid and vertebral arteries, jugular veins) and intracranially (carotid and basilar arteries, right sinus and superior longitudinal sinus). this analysis will be made possible by pcmri acquisitions with slice planes allowing the analysis of the dynamics of the csf (mesencephalic aqueduct, prepontic cisterns, foramen magnum, at the level of the c2c3 disc, syringomyelia if present), cerebellar tonsils (foramen magnum). the cross-sectional planes for hemodynamic analysis will be at the level of the c2c3 disc (cervical vascular analysis) and upstream of the polygon of willis (intracranial vascular analysis). the goal is to complement the clinical and morphological investigations with quantitative imaging of cerebrospinal fluid (csf) and blood flow in the craniospinal system. these flows are potentially altered or causes of this chiari anomaly. the investigators propose a translational research project of clinical research allowing the analysis of a diagnostic technique by a diagnostic, monocentric, prospective study. after neurosurgical consultation, patients with chiari malformation will be assigned to a symptomatic chiari malformation or a non-symptomatic chiari malformation group. they will be offered to participate in this study after information and informed consent. the allocation between the two groups will be made according to the symptomatic or non-symptomatic nature of the chiari malformation. after inclusion, the patients will have a morphological mri and a pcmri according to the determined slice plans and allowing a global analysis of the craniospinal hemohydrodynamics. craniospinal hemohydrodynamics in a control population will also be analyzed using the same methodology by pcmri.


Eligibility criteria:
inclusion criteria: * all patients with major symptomatic or nonsymptomatic cmi * aged 18 to 50 years * no previous neurosurgical, neurological, or cardiological history. * controls should be age-matched to symptomatic cmi group. they should not have a history of neurosurgery, neurology, or cardiology. exclusion criteria: * patients who are minors or over 50 years of age * cmi invalidated by our radiological review * neurosurgical, neurological or cardiological history * mri contraindication * pregnant, breast-feeding and parturient women

Keywords: type i chiari malformation cerebral hemodynamic craniospinal hydrodynamic phase contrast mri cerebrospinal fluid
tai chi intervention by telerehabilitation

Conditions: Parkinson Disease

Summary: rational : a lot of people in the province of quebec suffer from parkinson's disease and they are mostly vulnerable because they gradually lose their autonomy with the worsening of the disease. physiotherapy was proven to be an effective treatment method for these patients. however, accessibility to care remains a major issue. objective: this project aims to establish the clinical feasibility of a tai chi rehabilitation program through tele rehabilitation to patients suffering of parkinson's disease. methodology : this pilot study will be conduct with a pre/post-test device. therefore, to reach the objective, an evaluation will be done before the intervention and directly after the end of the 12 weeks program. also, the obstacles encountered during the interventions will be noted in a logbook. benefits: this is a priority research because its aim is to develop a care system that is efficient and accessible for a target population. the results of this study will confirm the possibility to put in place a telerehabilitation program who could reach, on a larger scale, more patients suffering from parkinson's disease.


Eligibility criteria:
inclusion criteria: * to be diagnosed with parkinson disease according to the " movement disorders society's diagnostic criteria " for at least 3 years * presence of a postural instability measured by the pull test according to movement disorders society-sponsored revision scale of unified parkinson disease rating scale " (mds-updrs) with a score to item 3, 12 ≥ 1, * have access to internet * have a caregiver available during rehabilitation sessions exclusion criteria: * have a une cognitive impairment measured by the " mini-mental state examination " (mmse), with a total score \< 24.

Keywords: tai chi telerehabilitation parkinson disease
the effects of noninvasive neuromodulation on mental wellness, behavior, and electrophysiology

Conditions: Anxiety Disorders

Summary: the purpose of the study is to test the effects of brief, low-intensity transcranial focused ultrasound (tus) on electrophysiological, behavioral, and cognitive markers related to anxiety disorders.

we will test the effects of tus on self-reported and clinical anxiety states in healthy participants and in those with diagnosed anxiety disorders. participants in these studies will receive pulsed tus to the brain regions of interest. we will test whether multiple doses of tus lead to larger reductions in mental states related to anxiety in comparison to a single dose of tus.

Eligibility criteria:
inclusion criteria: * 18-65 years of age, as verified via photo identification with date of birth. * should be an english speaker, as indicated by being able to read and comprehend the consent form. * experiment 2 : participants will be included for a past diagnosis of anxiety within the past year. exclusion criteria: * smokes or uses tobacco products or any form of nicotine excessively * history of head injury with loss of consciousness for more than 5 min * uncorrected hearing or vision impairment, including color blindness * currently have or history of brain or mental illness judged likely to interfere with testing, including drug and/or alcohol dependence * history of epilepsy * brain tumors * takes medications or drugs judged likely to change brain activity, including psychoactive drugs, stimulants, benzodiazepines, and/or others * factors that may lead to poor eeg or fnirs recordings (e.g., hairstyle) * inadequate sleep * drug, alcohol or prescription drug intoxication, dependence or addiction * pregnancy, or becoming pregnant during the course of the study * mild cognitive impairment or impaired decision making * history of migraines * experience with neurostimulation (which might unbind or alter the results) * metal implants in their head or face
role of exercise in diastolic heart failure

Conditions: Diastolic Heart Failure; Heart Failure With Preserved Ejection Fraction

Summary: diastolic heart failure is now being recognized as a key form of heart failure in older people. the focus of this research is to study ways to improve and maintain physical activity and functioning. this knowledge may improve the health and well-being in people with diastolic heart failure.

the purpose of this project is to better understand how endurance and fatigue relate to performing daily activities and how we might better improve endurance and reduce fatigue through an exercise program.

Eligibility criteria:
inclusion criteria: * age 60 and over * evidence of diastolic dysfunction on echocardiogram * normal left ventricular function (lvef≥50%) * heart failure-nyha class ii/iii * able and willing to participate in exercise program * able to come to ann arbor michigan for testing exclusion criteria: * regularly exercising(30 minute per day, 3 times per week) * orthopedic or musculoskeletal condition that limits weight bearing * uncontrolled atrial fibrillation * history of heart valve replacement * unstable or serious medical condition (ie. on dialysis, oxygen; severe anemia, uncontrolled blood pressure or coronary artery disease)
tai chi for comorbid depression in t2dm patients

Conditions: Depression; T2DM

Summary: previous studies suggested that tai chi may be beneficial for t2dm patients. however, no studies have investigated the effectiveness of tai chi for comorbid depression in t2dm patients, as well as the optimal frequency of tai chi. thus, we intend to investigate the effectiveness of tai chi for comorbid depression in t2dm patients and test whether the effectiveness of tai chi depends on its frequency.


Eligibility criteria:
inclusion criteria: * participants diagnosed with depression by experienced psychiatrist; * participants diagnosed with t2dm by experienced endocrinologist; * participants aged between 18\~75 years; * participants with hba1c ranges from 6.5% to 8.5%; * participants with hamilton depression scale (hamd) (24-item-version) ranges from 20\~35 scores; * participants passed the physical activity readiness questionnaire (par-q); * participants willing to complete 12-week intervention and 12-week follow-up. * participants willing to sign informed consent form. exclusion criteria: * participants with uncontrolled hypertension (sbp \>160mmhg or dbp \>100mmhg after taking hypotensive drugs); * participants with severe diabetic complications; * regular exercisers (at least 20 minutes/time, 3 times/week) in the last 3 months; * participants with cognitive impairment (montreal cognitive assessment \[moca\] scores \<26); * participants with history of bipolar disorder or schizophrenia or other mental illness; * participants with contraindications to exercise; * participants with acute, infectious diseases, cancer, or serious neurological disease, cardiovascular disease, pulmonary disease or other serious medical conditions limiting the ability; * participants taking psychoactive drugs; * participants participating in other clinical trials at the same time.

Keywords: tai chi depression t2dm randomized controlled trial
combinatorial therapy for peristent type 2 diabetes after gastric banding

Conditions: Type 2 Diabetes; Gastric Banding

Summary: the purpose of this study is to determine whether addition of 1 or 2 medicines after gastric banding can improve remission of type 2 diabetes.

liraglutide and orlistat improve glycemic control by increasing glucagon-like-peptide-1 (glp-1) response and fat malabsorption, respectively but do not reverse type 2 diabetes. roux-en-y gastric bypass (rygb) surgery reverses type 2 diabetes 84% of the time while the less invasive, reversible laparoscopic adjustable gastric banding (lagb) procedure reverses type 2 diabetes 48% of the time. decreased caloric intake occurs after rygb and lagb but increased post-prandial glp-1 response and fat malabsorption only occur after rygb. since fda-approved agents liraglutide and orlistat increase glp-1 response and fat malabsorption, respectively, it is of significant clinical interest to determine if addition of liraglutide and/or orlistat can improve type 2 diabetes remission rates in the 52% of patients who have not achieved diabetes reversal after gastric banding.

Eligibility criteria:
inclusion criteria: subjects will be eligible if they meet the following criteria: * male or female, * age 25-70 years, * bmi 26-65, * type 2 diabetic, * weight stable for 3 months, * status post laparoscopic adjustable gastric banding (lagb) for at least 1 year, * hemoglobin a1c 7-10%; * on any diabetic regimen including insulin except for thiazolidinedione use in the past 6 months. exclusion criteria: subjects will be excluded if they meet any of the following criteria: * prior history of pancreatitis, * prior history of gastroparesis, * glomerular filtration rate (gfr) \< 50, * history of thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary thyroid cancer, * history of cholelithiasis, * history of hyperoxaluria or calcium oxalate nephrolithiasis, * abnormal ast, * alt elevation, * current or past history of liver disease, * history of roux-en-y gastric bypass or gastric sleeve or any other bariatric procedure other than lagb, * type 1 diabetes, * any gastrointestinal disease causing malabsorption (including but not limited to inflammatory bowel disease, celiac sprue), * prior history of orlistat or incretin therapy use in past 3 months, * unwilling or unable to complete scheduled testing, * thiazolidinedione use within past 6 months, * any serious and/or unstable medical, psychiatric, or other condition(s) that prevents the patient from providing informed consent or complying with the study. patients who have had organ transplantation are on chronic anticoagulation, pregnant or have a1c values \> 10% will also be excluded.

Keywords: liraglutide orlistat
ear electro-stimulation for chronic pelvic pain

Conditions: Endometriosis

Summary: the brigham and women's pain management center is conducting a research study for chronic pelvic pain patients due to endometriosis. the study will assess the effect of electro-stimulation for the treatment of chronic pelvic pain. you may be eligible if you have chronic pelvic pain due to endometriosis, are between the ages of 21- 64, and not taking opioid medication (such as morphine or oxycodone). the study will require two visits, each lasting about 2 hours. the study takes place at the brigham \& women's pain management center, 850 boylston st., chestnut hill. please contact chrissie cahalan at 617-732-9014 or ccahalan1@partners.org if interested.

the brigham and women's pain management center is conducting a research study for chronic pelvic pain patients due to endometriosis. the study will assess the effect of electro-stimulation for the treatment of chronic pelvic pain. you may be eligible if you have chronic pelvic pain due to endometriosis, are between the ages of 21- 64, and not taking opioid medication (such as morphine or oxycodone). the study will require two visits, each lasting about 2 hours. the study takes place at the brigham \& women's pain management center, 850 boylston st., chestnut hill. please contact chrissie cahalan at 617-732-9014 or ccahalan1@partners.org if interested. vitaly napadow, ph.d., lic.ac. assistant professor dept. of radiology, massachusetts general hospital, harvard medical school

Eligibility criteria:
inclusion criteria: * female volunteers between 21 and 64 years of age with chronic pelvic pain for more than six months by self report. six months of chronic pain is the criteria most often used in cpp research. * cpp diagnoses will include endometriosis pain. * average pain intensity of ≥4 on a scale from 0 to 10, because \<4 is considered a level with acceptable pain and function * at least an 8th grade english-reading level; english can be a second language provided that the subjects feel they understand all the questions used in the assessment measures. exclusion criteria: * any interventional procedure for cpp two weeks prior to the study or during the two-week study period, such as lumbar epidural steroids, nerve root blocks, etc. * any etiology for cpp due to a known local somatic lesion for the pain (e.g. fibroids etc.) documented by the patient's gynecologist, surgery and/or imaging. we wish to focus on functional cpp, which may be more amenable to ravans due to the systemic nature of vns. * opioid usage, either oral or intrathecal. * surgical therapy in the previous 12 weeks, the intent to undergo surgery during the study period, or any clinically unstable systemic illness that is judged to interfere with the trial. * non-ambulatory status * history of cardiac or nervous system disease that, in the investigator's judgment, precludes participation in the study because of a heightened potential for adverse outcome. * an inability to complete questionnaires accurately. * cancer or other malignant disease, except carcinoma in situ of the skin * pregnancy
the effect of ylang ylang oil and lemon oil

Conditions: Pain, Labor; Anxiety; Aromatherapy

Summary: this study was conducted as a randomized controlled experimental study.to evaluate the effects of aromatherapy, one of the non-pharmacological pain methods, on labor pain and anxiety in the active phase in primiparous pregnant women. the main questions it aims to answer are: is ylang ylang oil applied as an inhaler effective in reducing labor pain and anxiety? is lemon oil applied as an inhaler effective in reducing labor pain and anxiety? participants randomized according to the closed envelope method into the lemon oil group (n=15), ylang ylang oil group (n=15) and control group (n=15). in the active phase (cervical dilatation ≥5), a drop of essential oil was instilled onto square cotton balls to the intervention groups and renewed as one drop every hour until labor occurred. in the control group, 1 drop of saline was dripped onto square cotton balls. visual pain scale (vas) and state anxiety ınventory were applied to the intervention groups and control groups before the application. after the application, vas and state anxiety ınventory were evaluated at 5-7 cm dilatation, and only with vas at 8-10 cm dilatation. the trait anxiety ınventory was administered to the volunteers after birth.


Eligibility criteria:
inclusion criteria: * term pregnancy (37-41 weeks) * pregnant women between the ages of 18-35 * had singleton pregnancy with cephalic presentation of the fetus * not allergic to ylang ylang oil, flower/lemon or oil or anything * absence of any pregnancy complications * no previous miscarriage, no abortion * not having any diagnosed systemic disease * ≥ 5 cm (cm) (active phase) cervical dilatation * pregnant women who do not take any analgesia, anesthesia or anxiolytic drugs * spontaneous onset of labor * pregnant women who can speak and write turkish well * pregnant woman's consent to participate in the study. exclusion criteria: * emergency cesarean section indication * use of analgesic, anesthetic and anxiolytic drugs by the pregnant woman * the pregnant woman's desire to withdraw from the study

Keywords: primiparous labor pain aromatherapy lemon oil ylang ylang oil
effect of balloon angioplasty vs stenting following residual stenosis after endovascular treatment of intracranial atherosclerotic acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the primary objective of this study is to evaluate whether rescue balloon angioplasty versus stenting for residual stenosis following endovascular therapy improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. patients will be randomized into two groups: the balloon angioplasty group receiving balloon treatment alone followed by standard medical therapy, and the stent group receiving stenting treatment with post-procedural standard medical therapy. the primary efficacy endpoint is the proportion of patients achieving functional independence (modified rankin scale 0-2) at 90±7 days, while the safety endpoint is the probability of symptomatic intracranial hemorrhage occurring within 48 hours after randomization.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. pre-stroke modified rankin scale (mrs) score of 0-1 3. acute ischemic stroke symptoms present within 24 hours of last known well time 4. baseline national institutes of health stroke scale (nihss) score ≥6 5. anterior circulation: alberta stroke program early ct score (aspects) ≥6 / posterior circulation: pc-aspects ≥6 6. occlusion of intracranial internal carotid artery (ica), m1 segment of middle cerebral artery (mca), v4 segment of vertebral artery, or basilar artery 7. clinical care team plans to perform endovascular thrombectomy (evt) 8. subject or legally authorized representative can provide informed consent 9. residual stenosis ≥50% with planned angioplasty/stenting exclusion criteria: 1. intracranial hemorrhage confirmed by imaging prior to randomization, or major intracranial hemorrhage on intraprocedural flat-panel ct 2. gastrointestinal or genitourinary bleeding within 30 days post-stroke onset, or major surgery within 14 days 3. bleeding diathesis including coagulopathy (platelets \ 50s, or inr \>2.0), doac use within 48 hours, or history of hit 4. pregnancy or lactation at admission 5. contraindications to radiographic contrast agents, nickel, titanium or their alloys 6. life expectancy \<6 months 7. pre-existing neurological/psychiatric conditions that may confound assessment 8. severe renal insufficiency (gfr \ 220μmol/l \[2.5mg/dl\]) 9. arterial tortuosity or anomalies preventing device delivery 10. unlikely to complete 90-day follow-up 11. any confirmed cardioembolic source (including atrial fibrillation, valvular disease, intracardiac thrombus, recent mi, cardiomyopathy with ef \<30%, etc.) 12. tirofiban or other gp iib/iiia inhibitor use before randomization or planned post-treatment

Keywords: acute ischemic stroke intracranial atherosclerotic remedial balloon therapy stenting endovascular treatment